(CercleFinance.com) – Sanofi gained almost 5% in Paris, taking advantage of its results on Dupixent and an analysis by Oddo which confirmed its outperformance rating, with an unchanged price target of 105 euros.
The analysis office thus judges as “extremely positive for the group” the positive results of the trial evaluating Dupixent in chronic bronchitis in smokers (COPD).
The analyst specifies that all of the primary and secondary endpoints were met in this trial, with in particular: i/ a statistically significant reduction (30%) in exacerbations vs. placebo, ii/ a significant improvement in lung function and iii/ a improvement in the patient’s quality of life.
‘With Dupixent and itepekimab, Sanofi has the ability to respond to the COPD market. This second asset is currently in phase III and the results are expected in 2025 (initially anticipated at the end of 2024 according to us),’ underlines Oddo.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
